Sleep Medications: Classes, Mechanisms, and Clinical Selection
A comprehensive review of hypnotic agents from historical perspectives to modern therapeutics
Sleep disorders affect approximately 30–40% of adults, with insomnia alone accounting for significant healthcare burden and impaired quality of life. The landscape of pharmacological treatment has evolved dramatically over the past 70 years, reflecting our changing understanding of sleep architecture, safety profiles, and addiction liability. This review synthesizes the clinical evidence on sleep medications across multiple drug classes, offering practical guidance for selecting agents based on insomnia phenotype, patient demographics, and comorbidities.
1. Historical Evolution of Sleep Medications
The pharmacological treatment of insomnia began in the late 19th century with barbiturates—potent, nonselective depressants of the central nervous system. Although effective at inducing sleep, barbiturates carried substantial risks of respiratory depression, tolerance development, and fatal overdose. Barbiturates dominated the market until the 1960s and remain notable historical landmarks in why modern sleep medicine has shifted toward safer agents.
Chloral hydrate (introduced 1869) and other chlorinated compounds offered some advantage in specificity but shared the tolerance and dependence liabilities of earlier generations. The 1960s saw the introduction of benzodiazepines—first diazepam (Valium), later triazolam (Halcion), temazepam (Restoril), and flurazepam (Dalmane). These offered improved selectivity for sleep promotion, though they ultimately proved to have their own addiction potential and complications (rebound insomnia, amnesia, falls in elderly populations).
The evolution from barbiturates → benzodiazepines → Z-drugs → modern agents (DORAs, melatonin agonists) reflects a fundamental principle: selectivity reduces side effects. Each generation sacrificed broad CNS depression for more targeted mechanisms of action.
Emerging Off-Label Agents
Despite regulatory status, several non-FDA-approved-for-insomnia agents have become widely prescribed:
- Trazodone: Currently the most commonly prescribed sleep medication in the U.S., though designed as an antidepressant. Used off-label for sleep in 24–64% of sleep medicine clinics.
- Gabapentin: Anticonvulsant with anxiolytic properties; useful in anxiety-predominant insomnia and neuropathic pain comorbidity.
- Quetiapine: Atypical antipsychotic; sedating properties exploit off-label use, though long-term metabolic risks are underappreciated.
- Hydroxyzine: First-generation antihistamine; shorter half-life (2 hrs) than diphenhydramine, reducing next-day impairment.
- Mirtazapine: Tricyclic-related antidepressant; effective for sleep, especially in depressed insomnia or when appetite stimulation desired.
2. Mechanisms of Action and Pharmacology
Modern sleep medications operate via distinct molecular targets, each with different efficacy and safety profiles:
Each class occupies a distinct niche in clinical practice. The choice between GABA-A modulators (faster onset), DORAs (maintained sleep architecture), and melatonin agonists (circadian alignment) depends on the insomnia phenotype and patient profile.
3. Evolving Indications and Clinical Attitudes
FDA Approval vs. Off-Label Reality
A critical disconnect exists between FDA-approved hypnotics and clinical practice. Only a handful of agents carry FDA approval for insomnia:
Benzodiazepine Devaluation
Benzodiazepines, once first-line agents, now occupy a diminished role due to:
- Beers Criteria recommendations: Avoid in adults ≥65 years due to increased risk of cognitive impairment, delirium, falls, and fractures.
- Dependence liability: 40–50% of chronic benzodiazepine users develop physical dependence within 4–6 weeks.
- Opioid–benzodiazepine co-prescribing warning (2016): FDA black box warning on concurrent use due to respiratory depression risk and overdose deaths. This restricted benzodiazepine prescribing in patients on opioids.
- Tolerance and rebound insomnia: Efficacy diminishes rapidly; abrupt discontinuation triggers severe rebound insomnia and anxiety.
As a result, benzodiazepines are now typically reserved for:
- Short-term use (1–2 weeks) in acute sleep crises
- Anxiety-predominant insomnia (though gabapentin or hydroxyzine are often preferred)
- Seizure disorder comorbidity (where benzodiazepine is therapeutic dual-purpose)
The Z-Drug Paradox
Z-drugs (zolpidem, zaleplon, eszopiclone) were heralded as safer alternatives to benzodiazepines due to selectivity for GABA-A α1 subunits. However, real-world evidence revealed a dark side: FDA black box for complex sleep behaviors (sleep-walking, sleep-driving, preparing meals while asleep). The FDA black box (2007) resulted in lower starting doses (5 mg instead of 10 mg for zolpidem) but did not substantially reduce prescribing, reflecting both their efficacy and the lack of alternatives.
Rise of DORAs and Modern Agents
The past decade has seen a paradigm shift toward newer, mechanism-based agents:
- Suvorexant (Belsomra, 2014): First DORA approved. Demonstrated efficacy in sleep maintenance; 12-hour half-life allows dosing at bedtime.
- Lemborexant (Dayvigo, 2019): Second-generation DORA with enhanced efficacy and longer half-life (~17 hours), improving nocturnal sleep architecture.
- Trazodone ascendancy: Despite off-label status, trazodone became the most-prescribed sleep agent in the U.S. by 2020, accounting for ~8 million prescriptions annually. This reflects both clinician comfort with an antidepressant (avoiding "addiction" stigma) and its dual action in depressed insomnia.
Clinical Pearl: The trazodone dominance is paradoxical. Off-label prescription carries no FDA safety monitoring, variable dosing (25–100 mg), and limited efficacy data in non-depressed insomnia. Yet it persists because it satisfies clinician concerns about benzodiazepine addiction while maintaining patient trust.
4. Side Effects and Safety Profiles Across Generations
Each drug class evolved to minimize the predecessor's toxicities:
| Drug Class | Key Side Effects | Most Serious Concern | Why Replaced |
|---|---|---|---|
| Barbiturates | Respiratory depression, tolerance, rebound insomnia | Lethal overdose (narrow therapeutic index) | Addiction liability & fatal in overdose |
| Benzodiazepines | Dependence, falls, amnesia, respiratory depression (dose-dependent) | Tolerance within 2–4 weeks; rebound insomnia on discontinuation | High abuse potential; risk in elderly; opioid interaction |
| Z-Drugs | Complex sleep behaviors, headache, next-day hangover (eszopiclone > zolpidem) | Parasomnias (FDA black box 2007) | Parasomnias; abuse potential still present (though lower) |
| DORAs | Sleep paralysis, hypnagogic hallucinations, somnolence, headache | Hypnagogic hallucinations can be distressing; rare cataplexy-like episodes in narcolepsy patients | Rare but concerning symptoms; still under-recognized |
| Melatonin Agonists | Headache, dizziness, somnolence | Minimal; FDA post-market surveillance shows excellent tolerability | Less efficacious for sleep maintenance |
| Low-Dose Doxepin | Dry mouth, sedation (minimal), weight gain (rare) | Anticholinergic effects if dosed >6 mg (cognitive impairment in elderly) | Requires low-dose formulation; historically used at higher doses |
| Trazodone | Dry mouth, orthostatic hypotension, priapism (rare), headache, next-day sedation | Orthostatic hypotension in elderly; SIADH (hyponatremia) | Off-label; lacks efficacy trials; under-recognized toxicity |
Side Effect Comparison Across Classes
Key Toxicity Patterns
- Dependence/tolerance trajectory: Barbiturates → benzodiazepines → Z-drugs each showed lower addiction liability but the trend plateaued at Z-drugs. DORAs and melatonin agonists show minimal tolerance.
- Falls in elderly: Benzodiazepines and Z-drugs both increase fracture risk 2–3-fold in adults ≥65 years, particularly with longer half-lives (flurazepam, eszopiclone).
- Parasomnias: FDA black box for Z-drugs (2007) reflects genuine risk of complex sleep behaviors. DORAs also carry this risk but at lower frequency.
- Next-day impairment: Z-drugs (especially eszopiclone) show dose-dependent next-day cognitive/psychomotor impairment; melatonin agonists and low-dose doxepin do not.
5. Choosing the Right Sleep Medication: A Clinical Algorithm
Rational hypnotic selection requires matching drug to insomnia phenotype, patient age, comorbidities, and duration of need:
6. Pharmacokinetics: Half-Life and Next-Day Impairment
Pharmacokinetic properties directly influence efficacy and side effects. Half-life determines whether a medication maintains sleep throughout the night and whether next-day sedation occurs:
Clinical Implications
- Zaleplon (1 hr): Ultra-short half-life ideal for middle-of-the-night awakenings; no next-day impairment even at standard doses.
- Zolpidem (2–3 hrs) & Eszopiclone (5–6 hrs): Intermediate duration appropriate for sleep onset; eszopiclone carries higher next-day impairment risk, especially in women and elderly (FDA recommends 1 mg in women, elderly).
- Temazepam (8–15 hrs) & Flurazepam (>48 hrs): Long-acting benzodiazepines problematic in elderly due to accumulation and next-day sedation. Flurazepam is contraindicated in older adults per Beers Criteria.
- DORAs (12–17 hrs): Intermediate half-life allows sleep maintenance without excessive next-day effect, though lemborexant's 17-hour half-life may cause mild morning drowsiness in some patients.
- Dosing caveat: Elderly patients demonstrate delayed drug clearance; standard doses of long-acting agents accumulate rapidly. Always initiate at 50% of standard dose in patients ≥75 years or with hepatic impairment.
7. Abuse Potential and Dependence Liability
Understanding addiction risk is critical for safe prescribing, particularly in patients with substance use disorder (SUD) history:
Risk Stratification Summary
8. Routine Monitoring and Discontinuation Strategies
Sleep medication is intended as a temporary intervention, yet many patients become long-term users. Systematic monitoring prevents dependence, toxicity, and identifies when deprescribing is appropriate:
Monitoring Framework
Essential Monitoring Questions at Each Visit:
- Ongoing need: Is sleep disorder still present? Has CBT-I been tried?
- Efficacy: Is the medication still working? (Tolerance screening)
- Adverse effects: Morning grogginess, falls, daytime impairment, memory issues?
- Dependence signs: Anxiety when medication unavailable? Dose escalation?
- Sleep quality objective measures: Sleep diary, actigraphy if available
- Safety in context: New medical conditions, drug interactions, age-related changes?
- Driving safety: Next-day alertness adequate? Recent accidents?
Fall Risk Assessment in Elderly
Avoid benzodiazepines and nonbenzodiazepine hypnotics (Z-drugs) in adults ≥65 years. Strong recommendation due to increased risk of cognitive impairment, delirium, falls, fractures, and motor vehicle crashes. If absolutely necessary, limit to 1–2 weeks maximum.
Benzodiazepines & Z-drugs: 1.5–2× increased fracture risk in elderly. Long-acting benzodiazepines (flurazepam) carry 3–4× risk. DORAs show similar risk (1.4–1.8×) but appear safer than traditional agents.
Low-dose doxepin (3 mg), melatonin agonists, and DORAs at reduced doses (lemborexant 5 mg in elderly) show better safety profiles. Consider non-pharmacologic CBT-I as first-line.
Periodic Discontinuation Trials
Patients on chronic hypnotics should undergo annual discontinuation trials to assess ongoing need and reset tolerance:
- Timing: Attempt taper in stable periods (no acute stress, psychiatric relapse, or medical exacerbation)
- Taper schedule: Reduce dose by 25% every 1–2 weeks (slow taper reduces rebound insomnia and withdrawal symptoms)
- Support: Reinforce CBT-I principles, sleep hygiene, relaxation techniques during taper
- Monitoring: Sleep diary, assess for anxiety, depressed mood, insomnia relapse
- Benchmarks: If sleep remains adequate off medication for 4 weeks, discontinuation successful. If relapse occurs, restart at lowest effective dose and re-attempt 6–12 months later.
Sleep Diary Use and Objective Measures
Sleep diaries quantify subjective sleep quality and track medication response over time. Key metrics:
Time to fall asleep after lights out. Target: <30 minutes. If SOL remains >45 min despite medication, consider agent switch or higher dose.
Total consolidated sleep. Target: 6–8 hours. Less may indicate ongoing insomnia; more may suggest hangover effect.
Total time awake after falling asleep. Target: <30 minutes. Persistent WASO suggests sleep maintenance failure.
Patient's rating on 1–10 scale. Combined with objective measures assesses both efficacy and tolerability.
9. References
- American Geriatrics Society. Beers Criteria Update 2023: American Geriatrics Society 2023 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults and Members of the American Academy of Clinical Pharmacy Summarize the Evidence. J Am Geriatr Soc. 2023;71(9):2760-2781.
- FDA. Black Box Warning for Nonbenzodiazepine Hypnotics. Drug Safety Communication. Published 2007, updated 2019. https://www.fda.gov/
- Riemann D, Krone LB, Wulff K, Nissen C. Sleep, insomnia, and depression. Neuropsychopharmacology. 2020;45(1):74-89.
- Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL. Clinical Practice Guidelines for Insomnia Disorder in Adults and Children: A Review by the American Academy of Sleep Medicine. J Clin Sleep Med. 2017;13(2):307-349.
- Schutte-Rodin S, Broch L, Buysse D, Dorsey CM, Sateia M. Clinical guideline for the evaluation and management of chronic insomnia in adults. J Clin Sleep Med. 2008;4(5):487-504.
- Winkelman JW. Insomnia disorder. N Engl J Med. 2015;373(15):1437-1444.
- Roehrs T, Roth T. Caffeine: Sleep and wakefulness. Sleep Med Rev. 2008;12(2):153-162.
- Morin CM, Benca R. Chronic insomnia. Lancet. 2012;379(9821):1129-1141.
- Krystal AD, Preskorn SH, Feustel A. Efficacy and safety of doxepin 1 and 3 mg in a 12-week sleep laboratory and outpatient trial of elderly subjects with chronic primary insomnia. Sleep. 2010;33(11):1553-1561.
- Citrome L, Stahl SM. Suvorexant: The first dual orexin receptor antagonist for insomnia. CNS Spectr. 2014;19(5):353-365.
- Winokur A, DeMartinis NA 3rd, McNally DP, et al. Efficacy and tolerability of eszopiclone in insomnia patients with generalized anxiety disorder: A 6-week, randomized controlled trial. J Clin Psychiatry. 2008;69(8):1214-1221.
- Perlis ML, Jungquist CR, Smith MT, Posner DA. Cognitive Behavioral Treatment of Insomnia: A Session-by-Session Guide. Springer Publishing; 2005.
- Lader M, Kyriakopoulos AA. The identification and assessment of dependence. Br J Addict. 1989;84(11):1265-1270.
- Everitt H, McDermott L, Leydon G, Nuttall S, Kendrick T. GPs' management of insomnia: a qualitative study. Br J Gen Pract. 2014;64(619):112-117.
- Qaseem A, Kansagara D, Forciea MA, Cooke M, Denberg TD. Management of chronic insomnia disorder in adults: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2016;165(2):125-133.
- Cunnington D, Junge MF, Fernando AT. Insomnia: prevalence, consequences and effective treatment. Med J Aust. 2013;199(S8):36-40.
- Bloom HG, Ahmed I, Alessi CA, et al. Evidence-based recommendations for the assessment and management of sleep disorders in older persons. J Am Geriatr Soc. 2009;57(5):761-789.
- Peck AW, Bye CE, Claridge R. Differences between light and heavy users of cannabis in patterns of prior drug use. Psychopharmacologia. 1972;25(2):122-132.
- Roth T, Walsh JK, Krystal A, et al. An evaluation of the efficacy and safety of eszopiclone over 12 months in patients with chronic primary insomnia. Sleep Med. 2005;6(6):487-495.
- Nutt DJ, Stahl SM. Searching for perfect sleep: the continuing evolution of GABA(A) receptor modulators for insomnia. J Clin Psychiatry. 2010;71(9):1086-1095.
- Carkadon MA, Dement WC. Normal human sleep: an overview. In: Kryger MH, Roth T, Dement WC, eds. Principles and Practice of Sleep Medicine. 6th ed. Elsevier; 2017:15-24.
Key Takeaway for Clinicians: Sleep medication selection is a nuanced decision balancing efficacy, side effect profile, abuse potential, and individual patient context. Modern practice favors DORAs, melatonin agonists, and low-dose doxepin in elderly patients; reserved use of benzodiazepines and Z-drugs; and judicious use of off-label agents when on-label options are inadequate. Always pair pharmacotherapy with cognitive-behavioral therapy for insomnia (CBT-I) and establish periodic monitoring to prevent long-term dependence. The "best" hypnotic is the one used shortest—the goal is sleep restoration and eventual independence from medication.